FDA Clears Novel Pain Treatment

News
Article

Seglentis’ co-crystal formulation targets four complementary pain relief mechanisms.

The FDA approved a first-in-class acute pain treatment. Seglentis, developed by Esteve, is made up of a co-crystal form of the anti-inflammatory celecoxib and the analgesic tramadol.

The multimodal treatment approach targets four complementary pain relief mechanisms and “offers a new treatment option for acute pain management aligned with the multimodal analgesia now considered standard of care,” the company said in a press release.

The novel co-crystal structure produces a unique pharmacokinetic profile of its active pharmaceutical ingredients compared with their individual or combined administration, according to the pharma maker.

Carlos Plata-Salamán, M.D.

Carlos Plata-Salamán, M.D.

"This innovation is the result of applying a crystallization technology to improve the physicochemical properties and pharmacokinetic characteristics of its active pharmaceutical ingredients,” Carlos Plata-Salamán, M.D., chief scientific officer and chief medical officer of Esteve, said in a statement. “The FDA approval means that clinicians and adult patients in the United States now have a new treatment option for acute pain management."

Seglentis will be commercialized in the United States by KOWA Pharmaceuticals America.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.